ERBB2 and breast carcinoma: In the third phase of the KAITLIN study (NCT01966471), researchers explored the potential of improving the treatment efficacy and reducing toxicity in HER2-positive early breast cancer (EBC) by using trastuzumab emtansine (T-DM1) as a replacement for taxanes and trastuzumab.